Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + oxaliplatin + fluorouracil
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three drugs: bevacizumab, oxaliplatin, and fluorouracil. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis and reducing tumor blood supply. Oxaliplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in cancer cells. Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and cell division. This combination is primarily used in the treatment of metastatic colorectal cancer, often as part of regimens such as FOLFOX or modified de Gramont protocols[1][2][3][4][5][6]. The addition of bevacizumab to oxaliplatin/fluorouracil-based chemotherapy has been shown to improve progression-free survival in patients with metastatic colorectal cancer[6][8].
- Other names
- FOLFOX/bevacizumabFOLFOX4/bevacizumabmFOLFOX6/bevacizumabBevacizumab-Fluorouracil-Oxaliplatin
02
Targets
TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on bevacizumab + oxaliplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + oxaliplatin + fluorouracil.